Teva
Teva’s white elephant plant in Mexico inoperative
November 14, 2016Manufacturing and Production Mexico, Rimsa, Teva
The Teva-Rimsa debacle continues to rumble on, with Teva’s plant in Mexico not producing any drugs for market. The plant …
Teva antihypertensive generic duo gets FDA thumbs up
November 7, 2016Manufacturing and Production, Sales and Marketing Azor, FDA, Teva, Tribenzor
Teva has received the approval from the US Food and Drug Administration (FDA) for its generic hypertension treatments Tribenzor (olmesartan …
Teva sets out to delay generic competitor to Copaxone
October 31, 2016Sales and Marketing Copaxone, Teva, Teva Pharmaceutical, generics
Teva Pharmacetuical, the Israel-based pharmaceutical company, submitted a document to the FDA on 30 October; the document outlines the differences …
Allergan in $200 million purchase of biopharmaceutical
October 28, 2016Medical Communications Allergan, Motus Therapeutics, Rythm Holding, Teva
Allergan will acquire Motus Therapeautics, a biopharmaceutical company that specialises in developing treatments for gastroparesis. It is another acquisition that …
Regeneron and Teva’s experimental drug halted by FDA clinical hold
October 17, 2016Manufacturing and Production Regeneron, Teva, back pain, osteoarthritis
Regeneron Pharmaceuticals and Teva Pharmaceuticals had only just agreed a deal worth a potential $2.6 billion to co-develop Regeneron’s fasinumab …
New UK & Ireland general manager for Teva
October 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, appointment
Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, …
Teva to sell Allergan’s UK & Ireland generics business for $770m
October 6, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva
Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.
Teva and Regeneron team up for $2.6 billion pain treatment development
September 21, 2016Research and Development, Sales and Marketing Regeneron, Teva, fasinumab, osteoarthritis
Teva and Regeneron have entered an agreement worth up to $2.6 billion to develop and market the latter’s experimental nerve …
Teva and Intel team up to tackle Huntington’s with wearable tech
September 16, 2016Medical Communications Huntington's, Intel, Teva, wearable tech
Israeli pharma firm Teva is joining forces with technology giant Intel to tackle the debilitating disease Huntington’s with cutting-edge wearable …
Top ten stories in the pharmaceutical industry this week
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis
It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …
Teva to lay off 236 in Pomona, New York
August 30, 2016Manufacturing and Production, Research and Development Teva, closure
Teva is currently in the process of winding down operations at its manufacturing plant in Pomona, New York as it …
Teva loses patent protection on lucrative MS treatment
August 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis
Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …
EU grants marketing authorisation for Teva’s asthma drug Cinqaero
August 19, 2016Medical Communications, Sales and Marketing EU, Teva, approval, asthma, cinqaero, eosinophilic
The European Commission has granted marketing authorisation for Teva’s Cinqaero (reslizumab), as an odd-on therapy in adult patients with severe …
Top ten stories in the pharmaceutical industry this week
August 5, 2016Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten
It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
Teva completes $40 billion acquisition of Actavis Generics
August 3, 2016Research and Development, Sales and Marketing Actavis, Allergan, Teva, acqusition, generics
Teva has announced that it has completed its acquisition of Actavis Generics, a subsidiary of Allergan, in a transaction valued …
